Patient baseline characteristics and clinical data for initial venetoclax (Ven1) and re-treatment (Ven2) regimens
| Baseline characteristics* . | Results . | (n = patients with available data) . |
|---|---|---|
| Median age at CLL diagnosis, y (range) | 55.5 (24-75) | n = 46 |
| Median age at Ven1 start, y (range) | 64 (31-75) | n = 46 |
| Male sex | 73.9% | n = 46 |
| Race | 83.3% White | n = 42 |
| 9.5% Black | ||
| 7.1% Other | ||
| Ven1 administered as part of a clinical trial | 56.5% | n = 46 |
| Ven1 as monotherapy | 37.0% | n = 46 |
| Ven1 as first-line treatment | 8.7% | n = 46 |
| Median prior lines of therapy (range) | 2 (0-10) | n = 46 |
| Prior BTKi | 40.0% | n = 45 |
| Del(17p) | 25.0% | n = 44 |
| TP53 mutation | 15.6% | n = 32 |
| Complex karyotype | 20.5% | n = 39 |
| IGHV unmutated | 82.1% | n = 39 |
| Rai stage at Ven1 start | 0: 4.9% | n = 41 |
| I: 26.8% | ||
| II: 19.5% | ||
| III: 17.1% | ||
| IV: 31.7% | ||
| TLS risk before treatment with Ven1 | Low: 32.6% | n = 46 |
| Medium: 34.8% | ||
| High: 32.6% | ||
| Ven1 regimen | Monotherapy: 37.0% | n = 46 |
| Ven-R: 47.8% | ||
| Ven-G: 4.3% | ||
| Ven-Ibrutinib: 2.2% | ||
| Other: 8.7% | ||
| Ven1 stable dose of 400 mg daily | 85.3% | n = 41 |
| Ven1 clinical or laboratory TLS | 6.1% (1 laboratory, 1 clinical) | n = 33 |
| TLS risk before treatment with Ven2 | Low: 47.1% | n = 34 |
| Medium: 38.2% | ||
| High: 14.7% | ||
| Ven2 regimen | Monotherapy: 45.7% | n = 46 |
| Ven-R: 28.2% | ||
| Ven-G: 10.9% | ||
| Ven-Ibrutinib: 4.4% | ||
| Other: 10.9% | ||
| Ven2 stable dose of 400 mg daily | 80.5% | n = 41 |
| Ven2 clinical or laboratory TLS | 8.6% (2 clinical; 1 unknown) | n = 35 |
| Baseline characteristics* . | Results . | (n = patients with available data) . |
|---|---|---|
| Median age at CLL diagnosis, y (range) | 55.5 (24-75) | n = 46 |
| Median age at Ven1 start, y (range) | 64 (31-75) | n = 46 |
| Male sex | 73.9% | n = 46 |
| Race | 83.3% White | n = 42 |
| 9.5% Black | ||
| 7.1% Other | ||
| Ven1 administered as part of a clinical trial | 56.5% | n = 46 |
| Ven1 as monotherapy | 37.0% | n = 46 |
| Ven1 as first-line treatment | 8.7% | n = 46 |
| Median prior lines of therapy (range) | 2 (0-10) | n = 46 |
| Prior BTKi | 40.0% | n = 45 |
| Del(17p) | 25.0% | n = 44 |
| TP53 mutation | 15.6% | n = 32 |
| Complex karyotype | 20.5% | n = 39 |
| IGHV unmutated | 82.1% | n = 39 |
| Rai stage at Ven1 start | 0: 4.9% | n = 41 |
| I: 26.8% | ||
| II: 19.5% | ||
| III: 17.1% | ||
| IV: 31.7% | ||
| TLS risk before treatment with Ven1 | Low: 32.6% | n = 46 |
| Medium: 34.8% | ||
| High: 32.6% | ||
| Ven1 regimen | Monotherapy: 37.0% | n = 46 |
| Ven-R: 47.8% | ||
| Ven-G: 4.3% | ||
| Ven-Ibrutinib: 2.2% | ||
| Other: 8.7% | ||
| Ven1 stable dose of 400 mg daily | 85.3% | n = 41 |
| Ven1 clinical or laboratory TLS | 6.1% (1 laboratory, 1 clinical) | n = 33 |
| TLS risk before treatment with Ven2 | Low: 47.1% | n = 34 |
| Medium: 38.2% | ||
| High: 14.7% | ||
| Ven2 regimen | Monotherapy: 45.7% | n = 46 |
| Ven-R: 28.2% | ||
| Ven-G: 10.9% | ||
| Ven-Ibrutinib: 4.4% | ||
| Other: 10.9% | ||
| Ven2 stable dose of 400 mg daily | 80.5% | n = 41 |
| Ven2 clinical or laboratory TLS | 8.6% (2 clinical; 1 unknown) | n = 35 |
G, obinutzumab; R, rituximab.
All baseline characteristics refer to Ven1 unless otherwise specified.